02.06.2020 – IGEA Pharma N.V.

IGEA announces changes in its board

IGEA Pharma N.V. / Key word(s): Miscellaneous
IGEA announces changes in its board

02-Jun-2020 / 22:50 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


IGEA announces changes in its board

Hoofddorp, the Netherlands, 2 June 2020. IGEA Pharma N.V. (SIX: IGPH) today
announced the nomination of Mr. Lieven Baten for election as non-executive
director of IGEA at the upcoming general meeting on 3 July 2020. Lieven
Baten is a partner at Acalis, with which IGEA has previously signed a
strategic partnership for the distribution of its products.

The CV of Lieven Baten is available at
https://www.igeapharma.nl/category/information-for-shareholders/ together
with the convening notice, the agenda, the explanatory notes and other
documents for the general meeting of 3 July 2020.


About IGEA
IGEA Pharma N.V. focuses on health-tech and med-tech products and devices.
Health-tech products are exclusively preventative. IGEA commercializes an
Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit
to measure non-bound copper in the blood and a natural dietary supplement
branded 'Alz1 Tab' designed to reduce blood heavy metals content), and
intends to launch a diabetes type II prevention set in 2020.
Non-ceruloplasmin bound copper is an expected Alzheimer's and diabetes type
II associated biomarker. Controlling non-bound copper can contribute to
reduce the risk of Alzheimer's and diabetes type II. Since 2020, IGEA
furthermore commercializes a COVID-19 rapid test for the detection of IgM
and IgG SARC-CoV-2 related antibodies. Med-tech products focuses on selected
solutions and specialities. IGEA commercializes dry aerosol generators for
air and inanimate environmental surfaces sanitization and air sterilization
and purification devices and expects to start commercializing medical bags
and other polymeric based specialty devices for medical use during 2020.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered
in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl

Vincenzo Moccia, CEO, +39 340 583 09 33, moccia@igeapharma.com
Patrick Pozzorini, CFO, +41 79 314 41 43, pozzorini@igeapharma.com

This document constitutes neither an offer to buy nor to subscribe
securities and neither this document nor any part of it should form the
basis of any investment decision in IGEA.

The information contained in this press release has been carefully prepared.
However, IGEA bears and assumes no liability of whatever kind for the
correctness and completeness of the information provided herein. IGEA does
not assume an obligation of whatever kind to update or correct information
contained in this press release whether as a result of new information,
future events or for other reasons.

This publication may contain specific forward-looking statements and
assessments or intentions concerning IGEA and its business. Such
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors which may result in a substantial divergence
between the actual results, financial situation, development or performance
of IGEA and those explicitly or implicitly presumed in these statements.
Against the background of these uncertainties, readers should not rely on
forward-looking statements. IGEA assumes no responsibility to update
forward-looking statements or to adapt them to future events or
developments, except as may be required by law.


End of ad hoc announcement